The Protective Role of Troxerutin (Trox) in Counteracting Anaplastic Thyroid Carcinoma (ATC) Progression

• Published in: Biomedicines Vol. 12; no. 8; p. 1755
• Main Authors: Bova, Valentina, Basilotta, Rossella, Casili, Giovanna, Lanza, Marika, Filippone, Alessia, Campolo, Michela, Capra, Anna Paola, Vitale, Giulia, Chisari, Giulia, Colarossi, Cristina, Giuffrida, Dario, Paterniti, Irene, Esposito, Emanuela
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.08.2024; MDPI
• Subjects: anaplastic thyroid carcinoma (ATC); anti-oxidant activity; antitumoral activity; Apoptosis; Bcl-2 protein; Biotechnology; Cancer therapies; Caspase-3; Cell adhesion & migration; chemotherapy; Glutathione; Heme oxygenase (decyclizing); Lymphocytes B; Manganese; NF-κB protein; Oxidants; Oxidative stress; Reactive oxygen species; Thyroid cancer; Thyroid carcinoma; troxerutin; United Kingdom > UK; United States > US; antitumoral activity; chemotherapy; troxerutin; anaplastic thyroid carcinoma (ATC); anti-oxidant activity
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12081755

Anaplastic thyroid carcinoma (ATC) is a rare thyroid neoplasm characterized by aggressiveness and a high mortality rate. Troxerutin (Trox) is a bioflavonoid widely found in various fruits and vegetables with numerous protective effects, including anticancer activities. To evaluate the anti-oxidant and anti-inflammatory effect of Trox, in vitro and in vivo studies were conducted in a model of ATC. Human ATC 8305C cell lines were treated with increasing concentrations of Trox (10 μg/mL, 30 μg/mL, 100 μg/mL, 300 μg/mL), and our results revealed that Trox treatment was able to reduce the viability of ATC cells and migratory capacity, reducing the expression of anti-apoptotic factors, such as B-cell lymphoma (bcl-2), and increasing the expression of pro-apoptotic factors, such as Caspase-3 and BID, activating oxidative stress mediators, such as manganese superoxide dismutase (MnSOD), heme oxygenase-1 (HO-1), glutathione (GSH) and reactive oxygen species modulator 1 (ROMO-1). Furthermore, Trox modulates NF-κB pathway markers, such as NIK and TRAF-6. Further confirmation was obtained through in vivo studies, in which Trox treatment, at doses of 12.5, 25 and 50 mg/kg, reduced morphological alteration, decreasing mast cell accumulation. Therefore, the use of Trox could be considered a promising strategy to counteract the progression of ATC.